Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSPE.L Regulatory News (SPE)

  • There is currently no data for SPE

Contract Win

16 Oct 2007 07:01

Sopheon PLC16 October 2007 Embargoed Release: 07:00hrs Tuesday 16 October 2007 Sopheon plc ('Sopheon') Beiersdorf Implements Sopheon System in Support of Product Innovation Strategy Accolade(R) Helps Skin Care Market Leader Integrate Management of Global Product Development Process Sopheon, the international software and services company, announced today thatBeiersdorf AG, a leading manufacturer of skin and beauty care products, hasdeployed Sopheon's Accolade product life cycle management (PLM) system tosupport the company's implementation of an enhanced, integrated process fordeveloping and launching new products. The solution is also being used tostrengthen product portfolio decision-making and reporting. Founded in Hamburg, Germany in 1882 by pharmacist Carl Beiersdorf, Beiersdorf'soriginal product patents were for bandages and wound coverings. By the turn ofthe century, the company had expanded into consumer skin care and beautyproducts. Today Beiersdorf is a $7B global producer of regionally brandedconsumer goods with approximately 100 locations and more than 17,000 employees. The company has a reputation for strong customer and product focus, anorientation that has helped, for instance, make NIVEA(R) the best-selling bodycare brand in the world. Cosmetics is a highly competitive, global industry. It is also among thefastest-moving markets in the consumer goods sector. The life of a typicalcosmetic product is only about four years, which means that ongoing, rapidinnovation is a prerequisite to achieving sustained business growth. Beiersdorfis addressing this imperative as a core aspect of its consumer businessstrategy, labeled "Passion for Success." The strategy calls for the company tofocus on fewer but more significant innovations and deliver them to marketfaster. Beiersdorf has long regarded continuous improvement of its new productdevelopment processes as a key factor in maintaining brand superiority. Beiersdorf's adoption of Accolade has allowed the company to advance not onlyits processes for product creation, but its portfolio management capabilities aswell. One principal benefit of the system is that it has given thecross-functional teams engaged in product development across the Beiersdorforganization a common platform through which to access and share project data.The result has been greater transparency and an improved ability to track theprogress of projects in the developmental pipeline. Accolade has also helped toraise the efficiency and accuracy of portfolio reporting and strengthen thecompany's portfolio management and decision-making processes. Sopheon partners Sopheon Vertriebs GmbH and Sopheon Business Applications GmbHwere responsible for the sale, implementation and support of Accolade atBeiersdorf. Dieter Jaeger, chief executive officer of Sopheon Vertriebs GmbH,said, "Beiersdorf has commanded a top position in the international personalcare market for many years, and innovation-led product development has been ahallmark of their success. When we were introduced to Beiersdorf, they alreadyhad in place a standardized, global product development process anchored in bestpractices. With Accolade, we were able to give them a single, user-friendlysoftware system that integrated the management of that process with portfoliomanagement and comprehensive decision-support. Beiersdorf chose Accoladebecause it could match their specific, demanding process requirements. Theyhave subsequently embraced it because it has proven that it helps to ensuresuperior process performance." Accolade(R) is a registered trademark of Sopheon plc. NIVEA(R) is a registered trademark of Beiersdorf AG. All other trademarks and registered trademarks are the sole property of their respective owners. About Beiersdorf AG Founded in Hamburg, Germany in 1882 as a small pharmacy, Beiersdorf has grown tobecome a global company of branded consumer goods with approximately 100affiliates. Since its founding, Beiersdorf has concentrated on skin and beautycare. Beiersdorf is focused on dynamic regions that have above-averagedevelopmental potential, including Asia, South America and Eastern Europe.Beiersdorf is particularly focused on China, Russia, Brazil and India.Beiersdorf products include NIVEA(R), Eucerin(R), Curad(R), Labello(R), 8x4(R),JUVENA(R), la prairie(R), atrix(R) and FUTURO(R). For more information, pleasevisit www.beiersdorf.com. About Sopheon Sopheon (LSE:SPE) is an international provider of software and services thathelp organizations improve the business impact of product innovation. Sopheon'ssolutions automate and govern the innovation process, enabling companies toincrease revenue and profits from new products. Sopheon is listed on the AIMMarket of the London Stock Exchange and on the Euronext in the Netherlands. Formore information, please visit www.sopheon.com. - Ends - For further information contact: Barry Mence, Chairman Sopheon plc Tel : + 44 (0) 1483 685 735Arif Karimjee, CFOAndrew Tan Hansard Tel : + 44 (0) 207 245 1100 + 44 (0) 7957 203 685Floor van Maaren Citigate First Financial Tel : + 31 (0) 205 754 010 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
6th Dec 20137:00 amRNSDirector/PDMR Shareholding
5th Dec 20137:00 amRNSCorporate Update
19th Nov 20137:00 amRNSSopheon Delivers Accolade® Release 9.0
7th Nov 20137:00 amRNSInterim Management Statement
11th Sep 20133:00 pmRNSHolding(s) in Company
4th Sep 20133:00 pmRNSHolding(s) in Company
22nd Aug 20137:00 amRNSInterim Results
15th Aug 20133:00 pmRNSHolding(s) in Company
29th Jul 20133:00 pmRNSHolding(s) in Company
26th Jul 20137:00 amRNSTrading Update
15th Jul 20134:15 pmRNSHolding(s) in Company
28th Jun 20133:00 pmRNSTotal Voting Rights
27th Jun 20133:00 pmRNSHolding(s) in Company
19th Jun 20133:42 pmRNSHolding(s) in Company
19th Jun 20137:00 amRNSNew capabilities with Accolade(R) 8.3
14th Jun 20132:00 pmRNSContract Win
12th Jun 201312:00 pmRNSResult of AGM & GM
12th Jun 20137:00 amRNSAGM Statement
4th Jun 20137:00 amRNSIssue of Shares
2nd May 20137:00 amRNSInterim Management Statement
21st Mar 20137:00 amRNSPreliminary Results
30th Jan 20137:00 amRNSTrading Update
23rd Jan 20137:00 amRNSLaunch of Accolade 8.2
7th Dec 201211:36 amPRNHolding(s) in Company
8th Nov 20127:00 amPRNInterim Management Statement
1st Oct 20127:00 amRNSHolding(s) in Company
1st Oct 20127:00 amRNSDirectors' Options
24th Sep 20127:00 amRNSMarket Transfer to NYSE Alternext Concluded
23rd Aug 20127:00 amRNSAmendment to Terms of Convertible Loan Stock
23rd Aug 20127:00 amRNSInterim Results
23rd Jul 20127:00 amRNSTrading Update
13th Jun 20123:14 pmRNSResult of AGM
13th Jun 20127:00 amRNSAGM Statement
15th May 20127:00 amRNSAmendment to terms of Convertible Loan Stock
3rd May 20127:00 amRNSInterim Management Statement
25th Apr 20127:00 amRNSLaunch of Accolade 8.0
22nd Mar 20127:00 amRNSPreliminary Results
16th Feb 20127:00 amRNSTop 10 Solution Provider to CGM
31st Jan 20127:00 amRNSTrading Update
23rd Dec 201112:32 pmRNSExtension of GEM Equity Line
23rd Dec 201112:29 pmRNSTrading Update
5th Dec 201112:40 pmRNSHolding(s) in Company
3rd Nov 20117:00 amRNSInterim Management Statement
25th Aug 20117:00 amRNSInterim Results
25th Jul 20117:00 amRNSTrading Statement
23rd Jun 20112:15 pmRNSDirector/PDMR Shareholding
15th Jun 20117:00 amRNSAGM Statement
5th May 20117:00 amRNSInterim Management Statement
24th Mar 20117:00 amRNSPreliminary Results
10th Feb 20117:00 amPRNAppointment of Adviser

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.